Regulation of the acetylcholine/α7nAChR anti-inflammatory pathway in COVID-19 patients - Archive ouverte HAL Access content directly
Journal Articles Scientific Reports Year : 2021

Regulation of the acetylcholine/α7nAChR anti-inflammatory pathway in COVID-19 patients

David Veyer
  • Function : Author
  • PersonId : 767415
  • IdRef : 126541264
Frédéric Pène
Bruno Charbit
Francis Berenbaum
Benjamin Terrier
Jérémie Sellam


The cholinergic system has been proposed as a potential regulator of COVID-19-induced hypercytokinemia. We investigated whole-blood expression of cholinergic system members and correlated it with COVID-19 severity. Patients with confirmed SARS-CoV-2 infection and healthy aged-matched controls were included in this non-interventional study. A whole blood sample was drawn between 9-11 days after symptoms onset, and peripheral leukocyte phenotyping, cytokines measurement, RNA expression and plasma viral load were determined. Additionally, whole-blood expression of native alpha-7 nicotinic subunit and its negative dominant duplicate (CHRFAM7A), choline acetyltransferase and acetylcholine esterase (AchE) were determined. Thirty-seven patients with COVID-19 (10 moderate, 11 severe and 16 with critical disease) and 14 controls were included. Expression of CHRFAM7A was significantly lower in critical COVID-19 patients compared to controls. COVID-19 patients not expressing CHRFAM7A had higher levels of CRP, more extended pulmonary lesions and displayed more pronounced lymphopenia. COVID-19 patients without CHRFAM7A expression also showed increased TNF pathway expression in whole blood. AchE was also expressed in 30 COVID-19 patients and in all controls. COVID-19-induced hypercytokinemia is associated with decreased expression of the pro-inflammatory dominant negative duplicate CHRFAM7A. Expression of this duplicate might be considered before targeting the cholinergic system in COVID-19 with nicotine. Coronavirus disease 19 (COVID-19) is characterized by clinical heterogeneity, with severity ranging from asymptomatic patients to critical and life-threatening disease 1. Severe and critical COVID-19 are characterized by an acute respiratory distress syndrome (ARDS) driven by an exacerbated inflammatory response that can lead to multi-organ failure and death 2. This hypercytokinemia, initially named "cytokine storm", is associated with high levels of circulating tumor necrosis factor (TNF) and interleukin-6 (IL-6), profound peripheral blood lymphopenia and chemoattraction of mononuclear cells within the lungs 3-5. Overall, this imbalanced inflammatory response is responsible for tissue damage and disease severity.
Fichier principal
Vignette du fichier
s41598-021-91417-7.pdf (1.44 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

hal-03251662 , version 1 (07-06-2021)



Alice Courties, Jeremy Boussier, Jérôme Hadjadj, Nader Yatim, Laura Barnabei, et al.. Regulation of the acetylcholine/α7nAChR anti-inflammatory pathway in COVID-19 patients. Scientific Reports, 2021, 11 (1), ⟨10.1038/s41598-021-91417-7⟩. ⟨hal-03251662⟩
60 View
29 Download



Gmail Facebook Twitter LinkedIn More